Lee Chan Joo, Choi Seungbum, Cheon Dong Huey, Kim Kyeong Yeon, Cheon Eun Jeong, Ann Soo-Jin, Noh Hye-Min, Park Sungha, Kang Seok-Min, Choi Donghoon, Lee Ji Eun, Lee Sang-Hak
Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Lipids Health Dis. 2017 Feb 28;16(1):49. doi: 10.1186/s12944-017-0433-6.
The influence of lipid-lowering therapy on high-density lipoprotein (HDL) is incompletely understood. We compared the effect of two lipid-lowering strategies on HDL functions and identified some HDL-related proteins.
Thirty two patients were initially screened and HDLs of 21 patients were finally analyzed. Patients were randomized to receive atorvastatin 20 mg (n = 11) or atorvastatin 5 mg/ezetimibe 10 mg combination (n = 10) for 8 weeks. The cholesterol efflux capacity and other anti-inflammatory functions were assessed based on HDLs of the participants before and after treatment. Pre-specified HDL proteins of the same HDL samples were measured.
The post-treatment increase in cholesterol efflux capacities was similar between the groups (35.6% and 34.6% for mono-therapy and combination, respectively, p = 0.60). Changes in nitric oxide (NO) production, vascular cell adhesion molecule-1 (VCAM-1) expression, and reactive oxygen species (ROS) production were similar between the groups. The baseline cholesterol efflux capacity correlated positively with apolipoprotein (apo)A1 and C3, whereas apoA1 and apoC1 showed inverse associations with VCAM-1 expression. The changes in the cholesterol efflux capacity were positively correlated with multiple HDL proteins, especially apoA2.
Two regimens increased the cholesterol efflux capacity of HDL comparably. Multiple HDL proteins, not limited to apoA1, showed a correlation with HDL functions. These results indicate that conventional lipid therapy may have additional effects on HDL functions with changes in HDL proteins.
ClinicalTrials.gov, number NCT02942602 .
降脂治疗对高密度脂蛋白（HDL）的影响尚未完全明确。我们比较了两种降脂策略对HDL功能的影响，并鉴定了一些与HDL相关的蛋白质。
最初筛选了32例患者，最终分析了21例患者的HDL。将患者随机分为两组，一组接受20mg阿托伐他汀治疗（n = 11），另一组接受5mg阿托伐他汀/10mg依折麦布联合治疗（n = 10），疗程8周。根据参与者治疗前后的HDL评估胆固醇流出能力和其他抗炎功能。检测相同HDL样本中预先指定的HDL蛋白。
两组治疗后胆固醇流出能力的增加相似（单药治疗组和联合治疗组分别为35.6%和34.6%，p = 0.60）。两组间一氧化氮（NO）生成、血管细胞黏附分子-1（VCAM-1）表达和活性氧（ROS）生成的变化相似。基线胆固醇流出能力与载脂蛋白（apo）A1和C3呈正相关，而apoA1和apoC1与VCAM-1表达呈负相关。胆固醇流出能力的变化与多种HDL蛋白呈正相关，尤其是apoA2。
两种治疗方案均可同等程度地提高HDL的胆固醇流出能力。多种HDL蛋白，不限于apoA1，与HDL功能相关。这些结果表明，传统的脂质治疗可能通过改变HDL蛋白对HDL功能产生额外影响。
ClinicalTrials.gov，编号NCT02942602 。
